Website: European Generic and Biosimilar Medicines Association

The European Generic and Biosimilar medicines Association represents the European generic and biosimilar pharmaceutical industries, which provide high-quality cost-competitive medicines to millions of Europeans. Companies represented within the EGA provide over 160,000 jobs in Europe. Generic medicines save EU patients and healthcare systems over €100 billion each year and account for 56% of all dispensed medicines but for only 22% of the pharmaceutical expenditure in Europe.

Formed in 1993, the EGA represents generic pharmaceutical companies and their subsidiaries from throughout Europe, either directly or through national associations. Companies represented within the EGA provide over 160,000 jobs in Europe. Without generic medicines, payers in Europe would have had to pay €100 BN more in 2014. Generic medicines help to ensure patient access to essential medicines and providing urgently needed budget headroom for the purchase of new and innovative treatments.

The EGA plays an important consultative part in European healthcare policy-making and provides key educational role for its members. The EGA and its members work with European national governments and the EU institutions to develop affordable solutions for pharmaceutical care and to increase Europe’s competitive strength in the global pharmaceutical medicines market.